News & Events

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.

MimiVax Phase 2 study of SurVaxM in combination with pembrolizumab opens for recurrent glioblastoma patients.

Buffalo, NY – MIMIVAX LLC, a clinical-stage biotechnology company in Buffalo, N.Y., USA, developing immunotherapeutics for cancer and autoimmune diseases,…
MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

MimiVax Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

https://www.prweb.com/releases/roswell_park_spinoff_company_advances_toward_new_clinical_trial_for_brain_cancer_immunotherapy_survaxm/prweb16737735.htm MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing…
MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

MimiVax LLC and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. announce exclusive licensing agreement on SurVaxM for glioblastoma treatment in China

Buffalo-based clinical-stage biotechnology company MimiVax, a Roswell Park Comprehensive Cancer Center spinoff, set to work with leading healthcare group in…
George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

George Washington University Researchers presenting at 2019 MGFA Scientific Session, AANEM Annual Meeting

Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in…
MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

MimiVax to present results of SurVaxM immunotherapy in glioblastoma at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International…
Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

Roswell Park Research on Survivin Opens Up New Avenues for Cancer Immunotherapy

Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research…
MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

MimiVax awarded Orphan Drug Designation by US FDA for SurVaxM to treat glioblastoma patients

Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded…
Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer

Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at…
Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative…